Trial Profile
Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone: Tolerance and Safety Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Fuchs' endothelial dystrophy; Hereditary corneal dystrophies; Keratoconus; Keratoplasty rejection
- Focus Therapeutic Use
- Acronyms IDEXACOR
- 01 Feb 2023 Results published in the British Journal of Ophthalmology
- 14 Aug 2019 Status changed from recruiting to completed.
- 29 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.